NVS · Novartis
Latest news, signals, and AI analysis for Novartis (NVS) on Catalayer. Updated continuously as stories are indexed across our news feed.
Recent NVS News
FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka - Fierce Pharma
Novartis to buy UK biotech Myricx Bio in $1.5bn deal - Financial Times
Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion - Bloomberg.com
Novartis to acquire UK-based Myricx Bio for up to $1.5 billion - Reuters
Related Tickers
$JNJ · Johnson & Johnson$LLY · Eli Lilly$PFE · Pfizer$MRK · Merck$ABBV · AbbVie$NVO · Novo NordiskFrequently Asked Questions
What sector does NVS belong to?
NVS (Novartis) is classified under the Pharma sector on Catalayer. You can browse all news in this sector at /sector/pharma.
Where can I track real-time NVS news?
Catalayer aggregates NVS coverage from Reuters, Bloomberg, CNBC, MarketWatch, Yahoo Finance, Seeking Alpha, Barron’s, WSJ, Motley Fool, Benzinga, TipRanks and 20+ other sources. View the live feed at https://catalayer.com/stocks/NVS.
How fast are NVS news alerts on Catalayer?
News is polled every 30–60 seconds. NVS-related stories appear in your workspace within minutes of publication, and you can create a custom monitor to get instant alerts.
Does Catalayer provide AI analysis for NVS?
Yes. The Market Intelligence tier adds AI-powered event classification (monetary policy, earnings, guidance, M&A), directional impact (bullish/bearish), magnitude, and affected-sector analysis to every NVS story.
Is NVS covered in any Catalayer signal channels?
Signal channels and custom keyword monitors both support NVS. Free accounts get 1 monitor; Plus ($29/mo) unlocks 5 monitors with boolean rules across tickers, sectors, and topics.